Search results
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 18 hours agoFinancial Highlights The company reported a net revenue of $14.8 million for Q1...period, reflecting...
Scientists identify new treatment target for leading cause of blindness
Science Daily· 6 days agoAMD is a condition characterized by abnormal blood vessel growth in the back of the eye. It is highly prevalent in the elderly and people with diabetes, ...
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including...
FOX21 Colorado Springs· 6 days ago(Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, ...
How to protect your vision
Rolling Out· 5 days agoOur eyes are windows to the world, allowing us to experience the beauty and wonder around us — until they start to deteriorate.
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days ago...NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the ...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 6 days ago...Journal from the International Macular and Retinal Foundation, Genentech's MyVisionTrack app, and...
Judi Dench says she was told she didn’t ‘have the face for film’ at start of career
The Independent via Yahoo News· 6 days agoLast year, Dench opened up about having age-related macular degeneration (AMD), revealing that she...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoWebinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Investor's Business Daily· 5 days agoRegeneron Pharmaceuticals missed on both metrics, with EPS down 5% and sales off 1% to $3.15...
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint
Market Watch· 2 days agoEyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
